09:54 AM EST - Novelion Therapeutics Inc. : Announced that its subsidiary has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in a subset of patients with partial lipodystrophy. Novelion Therapeutics Inc.
shares T.NVLN are trading up $0.18 at $11.90.
